PSPedro Henrique Imenez Silva

Pedro Henrique Imenez Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pedro Henrique Imenez Silva has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney Health in a Changing Climate

    by Suemy Melim Yamada, Marcella Cipelli, Pablo Shimaoka Chagas, Pedro Imenez Silva, Niels Olsen Saraiva Câmara

    Climate change has reshaped global health in unprecedented ways, with CKD increasingly recognized as a major climate-sensitive condition. Kidney diseases affect an estimated 850 million people worldwide, and countries with the highest incidence are often facing rapid social and economic vulnerability alongside sustained rises in annual temperatures. A growing body of evidence has demonstrated that recurrent heat exposure, failures in heat dissipation, and associated environmental stressors markedly increase the risk of acute kidney injury and accelerate its progression to CKD. On the other hand, epidemiological indicators reinforce this relationship, showing approximately a 30% increase in kidney disease morbidity in regions exposed to high heat, as well as heat-associated CKD epidemics in Central America, Mexico, India, and Sri Lanka, even in the absence of traditional risk factors. These patterns suggested that chronic heat stress and repeated dehydration during manual labor may act as catalysts that unmask metabolic vulnerabilities or enhance susceptibility to nephrotoxic exposures. In this review, we integrated robust population-level data with mechanistic biological insights to explain how these climatic trends disproportionately affect vulnerable populations. We examined historical and contemporary temperature trajectories, identified countries with the greatest climatic and epidemiological burden, and presented key indicators such as incidence, mortality, and clinically relevant population metrics. At the molecular level, we connected these findings to heat-sensitive pathways involving dehydration, mitochondrial dysfunction, tubular injury, inflammation, renal hypoperfusion, and uric acid stone formation. Finally, we situated these processes within the ecological and evolutionary context of human thermoregulation, highlighting a growing adaptation lag between accelerating global warming and the limits of human physiological resilience. Thus, we argued that a comprehensive understanding of these multilevel interactions, from environmental conditions to cellular metabolism, is crucial for shaping effective prevention efforts, early diagnostic strategies, and evidence-based policies capable of mitigating the global rise of heat-associated kidney disease.


  • Open Access

    The urine metabolomic signature of distal diuretics and diuretic-induced hyponatremia in patients with chronic kidney disease

    by Crissy F. Rudolphi, Usha Musterd-Bhaggoe, George J.G. Ruijter, Ewout J. Hoorn, Pedro H. Imenez Silva

    Recent clinical trials have shown that distal nephron-acting diuretics are effective in managing fluid retention and salt-sensitive hypertension in people with chronic kidney disease (CKD). However, their use may be complicated by diuretic-induced hyponatremia. This study aimed to characterize the metabolomic effects of distal diuretics in people with CKD, including those who develop hyponatremia. Therefore, we analyzed plasma and 24-hour urine samples from a previously completed randomized controlled trial including individuals with CKD (mean eGFR 39 ± 13 ml/min/1.73 m²) treated with amiloride/hydrochlorothiazide (5 mg/50 mg daily) for two weeks. The study included 26 participants in whom we analyzed a set of targeted metabolites. Global untargeted metabolomics was performed in a subcohort of 12 participants including 4 patients who developed hyponatremia (plasma sodium <136 mmol/L) and 8 diuretic-treated controls with stable sodium levels. Distal diuretic therapy decreased plasma glutamine levels and the excretion of several tricarboxylic acid (TCA) cycle-related metabolites. Furthermore, distal diuretics significantly increased urinary ammonium excretion in the absence of hypokalemia or metabolic acidosis. Untargeted metabolomic analysis revealed 988 unique metabolites in the urine. Among those with hyponatremia, we observed a metabolomic signature of oxidative stress, likely due to altered glutamine and carnitine metabolism. These findings suggest that distal diuretics not only act locally in the distal convoluted tubule but also influence proximal tubular metabolism. In conclusion, our results highlight that distal diuretics induce significant metabolic changes in CKD, with urine metabolomics offering valuable insights into the physiological pathways and mechanisms underlying both therapeutic effects and adverse responses.

  • Open Access

    Embracing Good Practices of Confirmatory Studies

    by Pedro Henrique Imenez Silva, Min Jun, Miriam Zacchia, Francesco Trepiccione, Giovambattista Capasso

  • Open Access

    Thiazide-induced hyponatremia

    by Sebastian B. Beckmann, Crissy F. Rudolphi, Pedro H. Imenez Silva, Robert A. Fenton, Ewout J. Hoorn


  • Open Access

    Acid excretion is impaired in calcium oxalate stone formers

    by Pedro H Imenez Silva, Nasser A Dhayat, Daniel G Fuster, Harald Seeger, Alexander Ritter, Thomas Ernandez, Florian Buchkremer, Beat Roth, Olivier Bonny, Isabel Rubio-Aliaga, et al.


  • Open Access

    Acid excretion is impaired in calcium oxalate stone formers

    by Pedro H Imenez Silva, Nasser A. Dhayat, Daniel G. Fuster, Harald Seeger, Alexander Ritter, Thomas Ernandez, Florian Buchkremer, Beat Roth, Olivier Bonny, Isabel Rubio-Aliaga, et al.

    Background: Urine pH is a key factor in kidney stone formation. We aimed to identify whether acid excretion capacity is disturbed in calcium oxalate (CaOx) or calcium phosphate (CaP) stone formers. Method: Urinary, serum, clinical, and anthropomorphic baseline data were obtained from the Swiss Kidney Stone Cohort, a prospective, longitudinal, and multi-centric observational study. We included in this study 193 non-stone formers (NSF, confirmed by negative CT scan), and 309 CaOx and 28 CaP stone formers. Titratable acids, net acid excretion (NAE), NAE capacity (NAEC) and acid-base (AB) score were calculated. Logistic regression analyses were used to estimate the potential associations of various acid-base variables with the occurrence of CaOx kidney stones. Results: CaOx stone formers showed a disturbed capacity to excrete acids in comparison to NSF (NAEC NSF = 3.49±12.6 mmol/24h; CaOx = −1.06±13.10; CaP = 0.97±14.70 and AB score NSF = 20.5±6.36 mmol/24h; CaOx = 17.9± 6.53; CaP = 18.8±6.10). The correlation between urine calcium and urine pH was altered in CaOx stone formers and between urine calcium and NAE was stronger in CaP stone formers. Logistic models showed that urinary ammonium was negatively associated with CaOx stone formation (unadjusted model, odds ratio 0.43[0.32-0.58], p< 0.001 for CaOx). Urine calcium was positively associated with CaOx kidney stones (2.85 [2.11-3.92], p<0.001). Similar results were obtained after adjusting for age, sex, and BMI. Replacing urine ammonium, pH, and phosphate with NAEC or ammonium and pH with AB score in our logistic regression models showed that NAEC and AB score are strongly associated with CaOx kidney stone formation. Conclusion: Ammonium excretion, NAEC and AB score are associated with the occurrence of CaOx kidney stones suggesting a potential role of proximal tubule dysfunction in their formation. CaP stone formers exhibit a disproportionately higher calcium excretion when acid excretion increases. Key learning points: What was known: Urine pH is a strong determinant in the formation of various urologically relevant crystals. Impaired urine acidification capacity has been observed in individuals who form calcium phosphate and uric acid stones. This study adds: When compared to non-stone formers, calcium oxalate stone formers are marked by a reduced capacity of excreting acids when urine pH becomes more acidic. Potential impact: The calculation of net acid excretion capacity and acid-base score are novel tools to identify those under potential higher risk of developing calcium oxalate stones.

  • Open Access

    The Effect of Thiazide Diuretics on Urinary Prostaglandin E2 Excretion and Serum Sodium in the General Population

    by Frank Geurts, Crissy F Rudolphi, Anissa Pelouto, Anna C van der Burgh, Mahdi Salih, Pedro Henrique Imenez Silva, Robert A Fenton, Layal Chaker, Ewout J Hoorn

    Context Thiazide-induced hyponatremia is one of the most common forms of hyponatremia, but its pathogenesis is incompletely understood. Recent clinical data suggest links with prostaglandin E2 (PGE2) and a single nucleotide polymorphism (SNP) in the prostaglandin transporter gene (SLCO2A1), but it is unknown if these findings also apply to the general population. Objective To study the associations between serum sodium, thiazide diuretics, urinary excretions of PGE2, and its metabolite (PGEM), and the rs34550074 SNP in SLCO2A1 in the general population. Design Prospective population-based cohort study (Rotterdam Study). Setting General population. Participants 2178 participants (65% female, age 64 ± 8 years) Intervention(s) None. Main Outcome Measure(s) Serum sodium levels. Results Higher urinary PGE2 excretion was associated with lower serum sodium: difference in serum sodium for each 2-fold higher PGE2 −0.19 mmol/L [95% confidence interval (CI) −0.31 to −0.06], PGEM −0.29 mmol/L (95% CI −0.41 to −0.17). This association was stronger in thiazide users (per 2-fold higher PGE2 −0.73 vs −0.12 mmol/L and PGEM −0.6 vs −0.25 mmol/L, P for interaction <.05 for both). A propensity score matching analysis of thiazide vs non-thiazide users yielded similar results. The SNP rs34550074 was not associated with lower serum sodium or higher urinary PGE2 or PGEM excretion in thiazide or non-thiazide users. Conclusion Serum sodium is lower in people with higher urinary PGE2 and PGEM excretion, and this association is stronger in thiazide users. This suggests that PGE2-mediated water reabsorption regulates serum sodium, which is relevant for the pathogenesis of hyponatremia in general and thiazide-induced hyponatremia specifically.


  • Open Access

    The mighty proton

    by Carsten A. Wagner, Pedro H. Imenez Silva

  • Open Access

    Ovarian cancer G protein-coupled receptor 1 deficiency exacerbates crystal deposition and kidney injury in oxalate nephropathy in female mice

    by Nima Yassini, Janine Sprenger, Eva Maria Pastor Arroyo, Christiane Krudewig, Giovanni Pellegrini, Nicole Joller, Carsten A. Wagner, Pedro Henrique Imenez Silva

    OGR1 (Gpr68) and GPR4 (Gpr4) are proton-activated G protein-coupled receptors that are stimulated upon increased extracellular acidity. These receptors have various physiological and pathophysiological roles in renal acid-base physiology, tissue inflammation, and fibrosis among others. Their function in injured renal tissue, however, remains mostly unclear. To address this, we investigated their role in crystalline nephropathy by increasing the oxalate intake of GPR4 KO and OGR1 KO mice. After 10 days of high-oxalate intake and 4 days of recovery, renal crystal content, histopathology, filtration function, and inflammation were assessed. While GPR4 deficiency did not show major alterations in disease progression, OGR1 KO mice had higher urinary calcium levels and exacerbated crystal accumulation accompanied by decreased creatinine clearance and urea excretion and a decreased presence of regulatory T (Treg) cells in kidney tissue. When lowering the severity of the kidney injury, OGR1 KO mice were more prone to develop crystalline nephropathy. In this setting, OGR1 KO mice displayed an increased activation of the immune system and a higher production of pro-inflammatory cytokines by T cells and macrophages. Taken together, in the acute setting of oxalate-induced nephropathy, the lack of the proton-activated GPCR GPR4 does not influence disease. OGR1 deficiency, however, increases crystal deposition leading to impaired kidney function. Thus, OGR1 may be important to limit kidney crystal deposition, which might subsequently be relevant for the pathophysiology of oxalate kidney stones or other crystallopathies.


  • The mechanisms of alkali therapy in targeting renal diseases

    by Pedro Henrique Imenez Silva, Donald E. Wesson, Carsten A. Wagner

    Chronic kidney disease (CKD) is characterized by progressive reduction in kidney function and treatments aiming at stabilizing or slowing its progression may avoid or delay the necessity of kidney replacement therapy and the increased mortality associated with reduced kidney function. Metabolic acidosis, and less severe stages of the acid stress continuum, are common consequences of CKD and some interventional studies support that its correction slows the progression to end-stage kidney disease. This correction can be achieved with mineral alkali in the form of bicarbonate or citrate salts, ingestion of diets with fewer acid-producing food components or more base-producing food components, or a pharmacological approach. In this mini-review article, we summarize the potential mechanisms involved in the beneficial effects of alkali therapy. We also discuss the perspectives in the field and challenges that must be overcome to advance our understanding of such mechanisms.